GlassScriptPhysician profile
Reema Naman
NPI 1124649892
$8,852.56
in general payments reported to CMS, 2019-2025
23 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $3,062 · 2023: $3,431 · 2024: $1,173 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,801 · Travel and Lodging: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.89 |
| Travel and Lodging | $1,691.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mid-Atlantic Surgical Systems, LLC | $2,781.81 | 2022-2023 | |
| Stryker Corporation | $2,020.25 | 2023-2025 | Prostep, Ortholoc 2 Lapifuse, Prostep Mica |
| Orthofix Medical, INC. | $1,049.66 | 2023 | Truelok |
| Smith+Nephew, INC. | $872.01 | 2021-2025 | Pico, Grafix Pl, Stravix Pl |
| Integra Lifesciences Corporation | $408.01 | 2023-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kerecis Limited | $312.78 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Depuy Synthes Sales INC. | $179.54 | 2024-2025 | Va-Lcp, Na, Motoband |
| Cumberland Pharmaceuticals, INC. | $157.01 | 2022-2023 | Caldolor |
| Abbvie INC. | $155.34 | 2024 | |
| Zak Ortho | $139.48 | 2024 | |
| Acera Surgical, INC. | $134.61 | 2023 | Restrata Wound Matrix |
| Heron Therapeutics, INC. | $123.39 | 2023 | Zynrelef |
| Amgen INC. | $110.76 | 2024 | Krystexxa |
| Treace Medical Concepts, INC. | $98.27 | 2024-2025 | |
| Convatec INC. | $63.93 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrofera LLC | $57.57 | 2023 | Hydrofera Blue |
| Averitas Pharma INC. | $54.28 | 2023 | Qutenza |
| Nevro Corp. | $40.73 | 2022-2023 | Senza |
| Zimvie INC. | $24.41 | 2022 | |
| Innovation Technologies INC | $22.63 | 2023 | Irrisept |
| Novo Nordisk INC | $20.07 | 2024 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2023 | Seglentis |
| Nabriva Therapeutics, Plc | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reema Naman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.